3 H]thymidine incorporation and a slight shift toward the S and G2/M phases of the cell cycle, whereas the combination of EGF and phorbol 12,13-dibutyrate (PDB) synergistically stimulated DNA synthesis. To investigate the effects of receptor-mediated PKC activation on mitogenesis, we demonstrated that ANG II induced ERK activation, a response completely blocked by pretreatment with mitogen/extracellular signal-regulated kinase inhibitors or specific PKC inhibitors. Furthermore, ANG II stimulated an over threefold increase in [
THE SEQUENTIAL proliferation, lineage-specific differentiation, migration, and cell death of epithelial cells of the intestinal mucosa is a tightly regulated process that is modulated by a broad spectrum of regulatory peptides (3, 15, 27) . The nontransformed IEC-6 and IEC-18 cells, derived from rat small intestinal crypt (22) , have provided an in vitro model to examine intestinal epithelial cell migration, differentiation, and proliferation (8, 12, 23, 27) . Previous studies have demonstrated that the proliferation and migration of these intestinal epithelial cells is regulated by polypeptide growth factors, including EGF, IGF-I, and hepatocyte growth factor, which act via single-pass transmembrane tyrosine kinase receptors (2, 8, 20) . Neuropeptides and vasoactive peptides that signal through seven-transmembrane G protein-coupled receptors (GPCRs) also act as potent cellular growth factors for a variety of cell types (25, 26) . However, the role of GPCRs, their ligands, and signal transduction pathways in intestinal epithelial cell proliferation remain poorly understood.
PKC, a major target for the tumor-promoting phorbol esters, has been implicated in the signal transduction pathways that mediate important functions in intestinal epithelial cells, including proliferation (1, 11) and carcinogenesis (21) . It is known that intestinal epithelial cells express multiple isoforms of the PKC family, including ␣, ␤, ␦, ⑀, and . Transgenic overexpression in murine colonic epithelium (19) or overexpression of certain PKC(s) in intestinal epithelial cells in culture has been shown to promote growth (18) . In contrast to these growth-stimulatory roles, certain PKCs, such as PKC-␣ (10, 11) and PKC-␦ (4), have been implicated in the mediation of growth-inhibitory signals in intestinal epithelial cells. Furthermore, biologically active phorbol esters, which directly activate PKCs, have been reported to inhibit cell cycle progression in logarithmically growing IEC-18 cells (10, 11) . Despite these studies in intestinal epithelial cells that are predominantly in the S/G 2 phase of the cell cycle, the role of PKC in the regulation of the exit from the G 0 /G 1 phase into DNA synthesis (S phase) in IEC-18 cells has not been previously investigated.
The central aim of the present study is to examine the role of PKC in the regulation of the transition from the G 0 /G 1 phase in DNA synthesis in IEC-18 cells. To achieve this aim, we used phorbol esters as a pharmacological tool to directly activate PKC and the octapeptide ANG II to examine receptor-mediated PKC activation in IEC-18 cells. We have previously reported that ANG II induces a dramatic increase in PKCdependent PKD activation in IEC-18 cells via the AT 1 receptor coupled to G q (6) and also stimulates in these cells a PKC-dependent increase in the tyrosine phosphorylation of Pyk2, a nonreceptor tyrosine kinase that has been implicated as an upstream element in ERK1/2 activation (32) . We used this model system to elucidate the role of PKC signaling in the reinitiation of the cell cycle of intestinal epithelial cells. We demonstrate, for the first time in IEC-18 cells arrested in G 0 /G 1 , that addition of phorbol 12,13-dibutyrate (PDB) combined with EGF synergistically and dramatically stimulates mitogenesis to levels comparable with that induced by ANG II. Our results indicate that ANG II induces cell cycle progression via the PKC-dependent pathway and thus indicate that phorbol ester-sensitive PKCs play a positive role in promoting exit from G 0 /G 1 and entry into S phase in IEC-18 cells.
MATERIALS AND METHODS
Cell culture. IEC-18 cells were purchased from the American Type Culture Collection. Stock cultures of these cells were maintained in DMEM supplemented with 5% FBS in a humidified atmosphere containing 10% CO2 and 90% air at 37°C. For experimental purposes, cells were plated in 100-mm dishes at 3 ϫ 10 5 cells/dish in DMEM containing 5% FBS and were allowed to grow to confluency (5-7 days) and then changed to serum-free DMEM for 18-24 h before the experiment.
Western blot analysis for ERK2/ERK1 activation and PKC isoforms. Serum-starved cultures of IEC-18 cells grown on 100-mm dishes were washed two times with DMEM and then treated as described in the individual experiments. The cells were lysed in 2ϫ SDS-PAGE sample buffer. After SDS-PAGE, proteins were transferred to Immobilon-P membranes (Millipore) and blocked by 3-6 h incubation with 5% nonfat milk in PBS, pH 7.2. Membranes were then incubated overnight with a specific anti-phospho-ERK1/ERK2 monoclonal antibody (MAb; New England Biolabs) that recognizes the phosphorylated state of Thr 202 and Tyr 204 of ERK1/2. The same membranes were stripped and probed in a similar fashion with goat anti-ERK2 polyclonal antibody.
For detection of PKCs or PKD, membranes were incubated overnight with an antiserum that specifically recognizes the phosphorylated state of Ser 916 of PKD at a dilution of 1:500 or with antibodies that specifically recognize the different PKC isoforms at a dilution of 1 g/ml, in PBS containing 5% nonfat dried milk.
Bound primary antibodies to immunoreactive bands were visualized by enhanced chemiluminescence detection with horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat antibodies. Autoradiograms were scanned using a GS-710 scanner (Bio-Rad), and the labeled bands were quantified using the Quantity One software program (Bio-Rad).
Assay of DNA synthesis. Confluent and serum-starved cultures of IEC-18 cells were washed two times with DMEM and incubated with DMEM/Waymouth's medium (1:1, vol/vol) and various additions as described in legends for Figs. 1-8. After 15 h of incubation at 37°C, [ 3 H]thymidine (0.2 Ci/ml, 1 M) was added, and the cultures were incubated for a further 4 h at 37°C. Cultures were then washed two times with PBS and incubated in 5% TCA at 4°C for 20 min to remove acid-soluble radioactivity, washed with ethanol, and solubilized in 1 ml of 2% Na 2CO3 and 0.1 M NaOH. The acid-insoluble radioactivity was determined by scintillation counting in 6 ml of Beckman Readysafe.
Flow cytometric/cell cycle analysis. The proportion of cells in the G 0/G1, S, G2, and M phases of the cell cycle was determined by flow cytometric analysis. Confluent and serum-starved cultures of IEC-18 cells were washed two times with DMEM and incubated with DMEM/Waymouth's medium (1:1, vol/vol) containing various additions as described in legends for Figs. 1-8. After 19 h of incubation at 37°C, cultures were washed two times with PBS. Cells were then detached by treatment with trypsin (0.025%), suspended in DMEM containing 10% FBS, and centrifuged at 1,000 g for 5 min. Cells (10 6 ) were then resuspended and stained by adding 1 ml of a hypotonic DNA staining buffer containing propidium iodide (0.1 mg/ml), sodium citrate (1 mg/ml), RNase A (20 g/ml), and Triton X-100 (0.3%). Samples were kept at 4°C, protected from light for 30 (10, 11) . From these results, the authors suggested that PKC mediates growth-inhibitory signaling in cells that are predominantly in S/G 2 phase of the cell cycle. However, the role of PKC in the regulation of the exit from the G 0 /G 1 phase into DNA synthesis (S phase) in IEC-18 cells has not been determined previously.
Initially, we examined the effect of PDB on the initiation of DNA synthesis by confluent and serumstarved cultures of IEC-18 cells incubated in the presence or absence of EGF, a well-known growth factor for intestinal epithelial cells. DNA synthesis was assessed by measuring (Fig. 1A) . In striking contrast, exposure of IEC-18 cells to PDB (100 nM) in the presence of EGF (5 ng/ml) led to a synergistic increase (3.5-fold) in [ Dose-response studies with EGF demonstrated that maximal [ 3 H]thymidine incorporation induced by this growth factor was achieved at 1-5 ng/ml (Fig. 1A,  inset) .
To investigate the synergistic interaction of PDB and EGF on the initiation of DNA synthesis by IEC-18 cells in more detail, we examined the effect of increasing concentrations of PDB (0.01-1,000 nM) on [ H]thymidine incorporation was synergistically increased when these cells were exposed to increasing concentrations of PDB in the presence of a fixed concentration of EGF (5 ng/ml). These findings suggested that PKC mediates mitogenic signaling in cells costimulated with EGF.
To substantiate that the stimulatory effect induced by PDB on [ (Fig. 2) . When PDB was added in the presence of EGF, the proportion of cells that entered S and G 2 /M increased synergistically in a dosedependent manner. Addition of 100 nM PDB combined with EGF induced a marked increase in the proportion of cells that entered S phase (from 11 and 14% in cells exposed to PDB or EGF to 35% in cells stimulated with PDB and EGF). These results further support the no- Fig. 1 . Phorbol 12,13-dibutyrate (PDB) and EGF synergistically stimulate thymidine incorporation. A: confluent and serum-starved cultures of IEC-18 cells were washed and incubated at 37°C in 2 ml DMEM/Waymouth's medium containing either 5 ng/ml EGF, 100 nM PDB, or 5 ng/ml EGF and 100 nM PDB. After 15 h, 1 Ci/ml [ 3 H]thymidine was added to the cultures, and 4 h later DNA synthesis was assessed by measuring the [ 3 H]thymidine incorporated in acid-precipitable material. Inset, confluent and serum-starved cultures of IEC-18 cells were washed and incubated at 37°C in 2 ml DMEM/Waymouth's medium containing vehicle or EGF at various concentrations as indicated. [ 3 H]thymidine incorporation was determined as described. cpm, Counts/min. Results shown means Ϯ SE; n ϭ 3 experiments. B: confluent and serum-starved cultures of IEC-18 cells were washed and incubated at 37°C in 2 ml DMEM/ Waymouth's medium containing PDB at various concentrations without (F) or with (E) 5 ng/ml EGF. [ 3 H]thymidine incorporation was determined as described. Results are means Ϯ SE; n ϭ 3 experiments. tion that PKC activation acts synergistically with EGF to stimulate progression through the cell cycle.
PKC ]thymidine incorporation and cell cycle progression of these cells. These effects could be explained by either the positive or the inhibitory limb of the dual actions attributed to PKC signaling on cell cycle progression. For example, PKC signaling in the first 2-6 h of PDB exposure could be sufficient to act synergistically with EGF to induce DNA synthesis. Alternatively, PDBinduced downregulation of classic and novel isoforms of PKC, a well-described effect of chronic treatment with biologically active phorbol esters in many cell types, could remove an inhibitory influence and thereby facilitate the positive effects of a synergistic growth factor (i.e., EGF). To distinguish between these alternative possibilities, it is necessary to dissociate PKC downregulation from PKC-mediated mitogenesis. In this context, it would be useful to identify a stimulus that induces PKC-dependent mitogenesis but does not downregulate any of the PKC isoforms.
ANG II is known to exert its biological effects through binding to the following two receptor subtypes: AT 1 and AT 2 receptors, which are members of the GPCR superfamily. Agonist binding to the AT 1 receptor induces PLC-mediated hydrolysis of membrane phosphoinositides, leading to the generation of two second messengers: inositol 1,4,5-trisphosphate, which stimulates Ca 2ϩ mobilization from intracellular stores, and diacylglycerol, which activates the classic and novel isoforms of the PKC family. PKD/PKC-, a serine/threonine protein kinase with structural, enzymological, and regulatory properties different from the PKC family members (14, 30) , has been identified as a downstream target of PKCs in a variety of cell types. Recently, we demonstrated that ANG stimulates potent activation of the PKC/PKD pathway in IEC-18 cells via an AT 1 receptor pathway (6) . In the present study, we examined whether ANG II not only induces PKC/PKD pathway activation but also alters the level of classic, novel, and atypical PKC isoforms in these cells.
To explore the effects of prolonged exposure of IEC-18 cells to ANG on PKC isoforms, serum-starved IEC-18 cells were treated with 200 nM ANG II for various times (0.5-24 h), and levels of PKC-␣, PKC-␦, PKC-⑀, and PKC-were measured by Western blotting using specific antisera directed against each of these isoforms. For comparison, parallel cultures of IEC-18 cells were treated with 100 nM PDB. As shown in Fig.  3A , levels of PKC-␣, PKC-␦, and PKC-⑀ diminished dramatically after PDB exposure. In contrast, prolonged exposure of IEC-18 cells to ANG II did not deplete PKC levels and led to a persistent PKD autophosphorylation at Ser 916 , indicative of persistent PKC activation (Fig. 3B) .
ANG induces DNA synthesis and cell proliferation. Having demonstrated that ANG II induces persistent PKC without detectable PKC downregulation (Fig. 3) , our next objective was to determine whether ANG II can stimulate DNA synthesis and cell proliferation in IEC-18 cells. To investigate the effects of ANG II on S phase entry in IEC-18 cells, serum-starved cultures of these cells were incubated with increasing concentrations of ANG II, and DNA synthesis was assessed by measuring [ To determine which ANG receptor subtype mediates the mitogenic effect of ANG II in IEC-18 cells, cultures of these cells were pretreated with either the selective AT 1 receptor antagonist losartan or the selective AT 2 receptor antagonist PD-123329 before addition of ANG II. As shown in Fig. 4B , pretreatment with losartan Interestingly, ANG II was more effective than EGF (at 5 ng/ml) in stimulating [ 3 H]thymidine incorporation in IEC-18 cells (Fig. 4C) . Addition of 100 nM PDB and 5 ng/ml EGF induced an increase in [ 3 H]thymidine incorporation by nearly fourfold, comparable with that induced by ANG II. Furthermore, exposure of these cells to both ANG II and EGF induced additive stimulation of DNA synthesis that reached a level almost comparable with that promoted by addition of medium containing 5% FBS.
To corroborate that ANG II induces cell cycle activation, we used flow cytometry to determine the distribution of IEC-18 cells through the various phases of the cell cycle, treated in the absence or presence of ANG II, EGF, or both. As shown in Fig. 5A, IEC-18 cells accumulated in the G 0 /G 1 phase of the cell cycle after serum starvation and addition of 50 nM ANG II induced a marked increase (from 8 to 21%) of cells in S phase of the cell cycle. Consistent with [
3 H]thymidine incorporation data, EGF induced a modest increase of cells in S phase, whereas the combination of ANG II and EGF stimulated a marked shift toward S and G 2 /M phase of the cell cycle.
To determine whether ANG II can stimulate IEC-18 cell proliferation in the absence of any other exogenously added growth factor, sparse cultures of these cells were transferred to serum-free medium and then stimulated with or without 100 nM ANG II. As shown in Fig. 5B , there was nearly a doubling in the cell number of cultures treated with ANG II for 24, 48, and 72 h compared with the controls.
The results presented in Figs. 4 and 5 indicate that ANG II acts as a potent growth factor for IEC-18 cells, and those depicted in Fig. 3 clearly demonstrate that this agonist induces persistent PKC/PKD pathway activation without concomitant PKC downregulation. To determine whether PKC downregulation is dissociable from PKC-mediated mitogenesis in ANG II-treated cells, we next determined the contribution of PKC to the mitogenic activity of ANG II.
To test whether ANG II-induced DNA synthesis is PKC dependent, cultures of IEC-18 cells were preincubated for 1 h with the selective PKC inhibitor GF-I (at 3.5 M). Control cells received either an equivalent amount of solvent or GF-V (also at 3.5 M), a biologically inactive analog of GF-I, before addition of ANG II. As shown in Fig. 6A , GF-I markedly reduced [ 3 H]thymidine incorporation was determined as described. Results are means Ϯ SE; n ϭ 3 experiments. C: ANG II is a more effective mitogen than EGF. Confluent and serum-starved cultures of IEC-18 cells were washed and incubated at 37°C in 2 ml DMEM/ Waymouth's medium containing vehicle, 5 ng/ml EGF, 100 nM PDB, 100 nM PDB and 5 ng/ml EGF, 50 nM ANG II, 5 ng/ml EGF and 50 nM ANG II, or 5% FBS. [ 3 H]thymidine incorporation was determined as described. Results are means Ϯ SE; n ϭ 3 experiments.
kinases that are directly activated by phosphorylation on specific tyrosine and threonine residues by the dualspecificity ERK kinase [or mitogen/extracellular signal-regulated kinase (MEK); see Ref. 31 ].
Cultures of IEC-18 cells were treated with increasing concentrations of ANG II and lysed, and the active forms of ERK1/2 were detected by Western blotting using an antibody that recognizes the dually phosphorylated forms of these enzymes. ERK1/2 activation was a rapid consequence of ANG II stimulation of IEC-18 cells, reaching a maximum within 2.5 min (Fig. 7A) . Furthermore, ANG II induced ERK1/2 activation in a Fig. 5 . ANG II stimulates DNA synthesis. A: confluent and serumstarved cultures of IEC-18 cells were washed and incubated at 37°C in 2 ml DMEM/Waymouth's medium containing vehicle, 5 ng/ml EGF, 50 nM ANG II, or both EGF and ANG II. After 19 h of incubation at 37°C, cultures were washed two times with PBS, and cells were detached by treatment with trypsin (0.025%). Cells (10 6 ) were then resuspended and stained by 1 ml of a hypotonic DNA staining buffer containing propidium iodide (0.1 mg/ml), sodium citrate (1 mg/ml), RNase A (20 g/ml), and Triton X-100 (0.3%). Samples were kept at 4°C, protected from light for 30 min, and analyzed on a FACScan (Becton-Dickinson). Results shown are representative of 3 independent experiments. B: ANG II stimulates IEC-18 cell proliferation; 5 ϫ 10 4 IEC-18 cells were plated on 35-mm Nunc petri dishes with 2 ml DMEM containing 1% FBS. At day 0 (24 h after plating), cultures were washed two times with DMEM to remove residual serum and replaced with DMEM/Waymouth's medium (1:1, vol/vol) with (open bars) or without (filled bars) 100 nM ANG II. Cell number was determined by counting trypsinized cells using a Coulter counter. Cell counts were obtained at day 0 (24 h after plating) and 24 (day 1), 48 (day 2), and 72 (day 3) h after ANG II exposure. *P Ͻ 0.01 vs. DMEM control for the respective day. concentration-dependent fashion, achieving half-maximal and maximal activation at 1 and 10 nM, respectively (Fig. 7B) .
As shown in Fig. 7C , ANG II-induced ERK1/2 activation in IEC-18 cells was completely prevented by pretreatment of these cells with the selective AT 1 receptor antagonist losartan, whereas preincubation with the selective AT 2 receptor antagonist PD-123329 before addition of ANG II had no effect. We conclude that ANG II induces PKC/PKD activation, ERK1/2 activation, and DNA synthesis via AT 1 receptors in IEC-18 cells.
To determine whether ANG II-induced activation of the ERKs is mediated by MEK in IEC-18 cells, cultures of these cells were preincubated for 1 h in the absence or presence of the specific MEK inhibitors PD-98059 (2) or U-0126 (9) and subsequently stimulated with ANG II. The results shown in Fig. 7D demonstrate that exposure to either PD-98059 or U-0126 completely prevented ERK1/2 activation in response to ANG II.
To establish whether DNA synthesis in response to ANG II is mediated by MEK-dependent ERK1/2 activation, serum-deprived cultures of IEC-18 cells were preincubated for 1 h in the absence or presence of the specific MEK inhibitors PD-98059 or U-0126 and subsequently stimulated with ANG II. As shown in Fig.  6B , treatment with either PD-98059 or U-0126 attenuated [ 3 H]thymidine incorporation in response to ANG II stimulation by ϳ50%.
ANG-induced ERK1/2 activation is PKC dependent.
Because we demonstrated that ANG II is a potent growth factor for IEC-18 cells (Figs. 4 and 5 ) through a PKC-dependent pathway (Fig. 6A ) and ERK1/2 activity is required for ANG II-stimulated DNA synthesis (Fig. 6B) , we next determined whether PKC is also required for ERK1/2 activation in response to ANG II. Initially, we investigated whether direct PKC activation by PDB can stimulate ERK phosphorylation. Stimulation of IEC-18 cells with PDB (100 nM) for various times indicates that PDB induces ERK1/2 activation rapidly, reaching a maximum within 2.5 min (Fig. 8A) . Furthermore, PDB induced ERK1/2 activation in a concentration-dependent fashion, achieving half-maximal and maximal activation at 10-30 and 100 nM, respectively (Fig. 8B) . To determine whether PDB-induced activation of the ERKs is mediated by MEK in IEC-18 cells, cultures of these cells were preincubated for 1 h in the absence or presence of the specific MEK inhibitor PD-98059 or U-0126 and subsequently stimulated with PDB. The results shown in Fig. 8C demonstrate that exposure to either MEK inhibitor completely prevented ERK1/2 activation in response to PDB.
GPCRs are known to induce ERK1/2 activation through multiple signal transduction pathways, including PKC-dependent and PKC-independent pathways. Because the results shown in Fig. 7 indicate that ANG II induces ERK activation and those shown in Fig. 8A indicate that PKC is a potential signaling pathway that can lead to ERK activation, we examined the contribution of PKCs to ANG II-induced ERK1/2 activation in IEC-18 cells. As shown in Fig. 8D , pretreatment of these cells with the specific PKC inhibitors GF-I and Ro-31-8220 prevented ANG II-induced ERK1/2 activation. In contrast, preincubation of cultures with GF-V, a biologically inactive analog of GF-I, had no effect on ANG II-induced ERK1/2 activation. These results suggest that ANG II-induced ERK1/2 activation is largely mediated by PKC in IEC-18 cells. These results do not exclude the possibility of a PKCindependent pathway, which may play a minor role in ANG II-induced ERK activation in IEC-18 cells.
Taken together, these results imply that PKC plays an important role in mediating ERK activation and reinitiation of DNA synthesis induced by either pharmacological (PDB) or physiological (ANG II-AT 1 receptor) stimulation of intestinal epithelial IEC-18 cells. Consistent with this, concomitant pretreatment with PKC inhibitor GF-I (2.5 M) and MEK inhibitor U-0126 (2.5 M) did not have an additive inhibitory effect on [ 
DISCUSSION
The proliferation of epithelial cells of the intestinal mucosa is a highly precise process that is modulated by a broad spectrum of peptides (3, 15, 27) , but the signal transduction pathways involved in intestinal cell proliferation remain poorly characterized. Nontransformed IEC-18 cells, derived from rat ileal crypts, have served as an in vitro model for studying intestinal epithelial cell migration, differentiation, and proliferation (8, 12, 23, 27) .
In actively cycling IEC-18 cells (cells growing in 5% serum), treatment with biologically active phorbol esters transiently delayed cell cycle progression, which was noted 2-6 h after treatment (10, 11) . This cellcycle delay was associated with a rapid decrease in the level of cyclin D 1 , which subsequently rebounded and in fact increased over the basal levels at later times of phorbol ester treatment (10) . From these results, the authors suggested that PKC mediates growth-inhibitory signaling in cells that are predominantly in S/G 2 phase of the cell cycle. However, the role of PKC in the regulation of the exit from the G 0 /G 1 phase in DNA synthesis (S phase) in IEC-18 cells has not been determined previously. The central aim of the present study was to examine the role of PKC in the regulation of the transition from the G 0 /G 1 phase in DNA synthesis in IEC-18 cells.
A salient feature of the results presented here is that stimulation of IEC-18 cells with the combination of EGF and PDB synergistically stimulated DNA synthesis as judged by either [ 3 H]thymidine incorporation in DNA or flow cytometric analysis to determine the proportion of cells in the various phases (G 0 /G 1 , S, and G 2 /M) of the cell cycle. Our results demonstrate, for the first time, that direct activation of PKC, as induced by a biologically active phorbol ester, strikingly potentiates the ability of EGF to stimulate cell cycle progression in IEC-18 intestinal epithelial cells.
Phorbol ester-sensitive isoforms of PKC have been implicated in both positive and negative regulation of the cell cycle, and phorbol esters are well known to produce downregulation of PKC proteins after their acute catalytic activation. Consequently, the mitogenic effects of PDB could be explained by either the stimulatory or the inhibitory limb of the dual actions attributed to PKC signaling on cell cycle progression. Specifically, PKC signaling in the first 2-6 h of PDB exposure could be sufficient to act synergistically with EGF to induce DNA synthesis. Alternatively, PDB-induced downregulation of classic and novel isoforms of PKC could remove an inhibitory influence and thereby facilitate the positive effects of EGF. To distinguish between these possibilities, we attempted to identify a stimulus that induces PKC-dependent mitogenesis but does not downregulate any of the PKC isoforms.
Recently, we demonstrated that ANG stimulates potent activation of the PKC/PKD pathway in IEC-18 cells via an AT 1 receptor pathway (6) . We also found that ANG II stimulates in these cells a PKC-dependent increase in the tyrosine phosphorylation of Pyk2, a nonreceptor tyrosine kinase that has been implicated as an upstream element in ERK1/2 activation (32). In the present study, we demonstrate that ANG II is a potent growth factor for IEC-18 cells, as shown by [ 3 H]thymidine incorporation in DNA, flow cytometric analysis to determine the proportion of cells in the various phases of the cell cycle, and assays of cell proliferation. The level of DNA synthesis induced by ANG II is substantially higher than that promoted by EGF and is comparable to that induced by the combination of EGF and PDB. Our results demonstrate that the mitogenic activity of ANG II is mediated by an AT 1 receptor subtype. Recently, we demonstrated that the peptide agonist vasopressin via GPCR V 1A receptor also induced DNA synthesis and cell proliferation in IEC-18 cells (7), indicating that the regulation of intestinal cell proliferation by GPCR agonists could be more common than previously suspected. Of special interest in the context of this study, treatment with ANG II did not induce any detectable downregulation of PKC isoforms but produced a persistent activation of PKD, a well-established downstream target of PKCs. Thus our results indicate that depletion of PKCs is clearly not responsible for the growth-stimulatory effect of ANG II in IEC-18 cells.
Subsequently, we determined the contribution of PKC to ANG II-induced mitogenesis and attempted to identify intermediate steps between PKC and cell cycle activation. Our results demonstrate that treatment with selective PKC inhibitors attenuated DNA synthesis in response to ANG II, implying that PKC downregulation can be dissociated from PKC-mediated mitogenesis. Our results indicate that PKC plays a stimulatory role in promoting exit of epithelial intestinal cells from quiescence. Because previous studies suggested that PKC delays cell cycle progression in growing cells (i.e., cells distributed in various phases of the cell cycle), it is conceivable that PKCs could play different roles in cell proliferation at different stages of the cell cycle (17) . In this context, it is of interest that our laboratory has recently demonstrated that overexpression of PKD potentiated DNA synthesis and cell proliferation in Swiss 3T3 fibroblasts in response to GPCR agonists (33) .
The MAPKs are a family of highly evolutionary conserved kinases connecting cell-surface receptors to critical regulatory targets within cells, and they regulate important cellular processes, including gene expression, cell proliferation, and cell motility (5). These serine/threonine kinases are activated by a range of extracellular signals via protein phosphorylation cascades (24) , which relay mitogenic signals to the nucleus (16) , thereby modulating the activity of transcription factors (29) . The two best-characterized isoforms, p42 mapk (ERK2) and p44 mapk (ERK1), are directly activated by phosphorylation on specific tyrosine and threonine residues by the dual-specificity ERK kinase (or MEK; see Ref. 28) .
Here, we show that addition of ANG II to IEC-18 cells stimulates MEK-dependent ERK1/2 activation. Furthermore, we have established that ANG II-in-duced ERK1/2 activation is PKC dependent, suggesting that PKC is a critical kinase that lies upstream of MEK/ERK in these cells. Using selective inhibitors of MEK, we found that ERK1/2 inhibition attenuated ANG II-induced DNA synthesis. These findings indicate that ANG II-induced stimulation of the AT 1 receptor subtype, endogenously expressed by IEC-18 cells, leads to PKC/PKD activation and stimulation of the ERK pathway and induces progression though the cell cycle of these cells arrested in G 0 /G 1. ANG II, the principal active component of the renin-ANG system (RAS), is traditionally recognized for its role in the regulation of systemic blood pressure and body fluid homeostasis. Recently, all RAS components [angiotensinogen, renin, and ANG-converting enzyme (ACE)] mRNA transcripts were found in human colonic mucosa (13) . Furthermore, immunohistochemical examination of these colonoscopic biopsies revealed renin and ACE to be localized in vessel walls, mesenchymal cells in the lamina propria, and parts of the surface epithelium (13) . Therefore, it is likely that ANG II is normally produced in intestinal tissues and may act as a local mediator in the control of intestinal functions, suggesting that, in addition to its well-known role as an endocrine hormone found in blood, ANG II may also act as a paracrine signaling peptide in the intestine.
In summary, we demonstrate, for the first time, that addition of PDB combined with EGF synergistically stimulates reinitiation of DNA synthesis in IEC-18 cells arrested in G 0 /G 1 . Our results also show that ANG II is a potent growth factor for IEC-18 cells via the AT 1 receptor subtype. ANG II induces cell cycle progression via a PKC-dependent pathway, supporting the notion that phorbol ester-sensitive PKCs play a positive role in promoting exit from G 0 /G 1 and entry in S phase in IEC-18 cells. Furthermore, ANG II-induced DNA synthesis is partially ERK dependent. Taken together, our results imply that PKC plays an important role in mediating early ERK activation and subsequent reinitiation of DNA synthesis induced by either pharmacological (PDB) or physiological (ANG II-AT 1 receptor) stimulation of quiescent intestinal epithelial IEC-18 cells.
